Cambridge Advisors Inc. Decreases Stock Holdings in Danaher Co. (NYSE:DHR)

Cambridge Advisors Inc. cut its holdings in Danaher Co. (NYSE:DHR) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,213 shares of the conglomerate’s stock after selling 313 shares during the quarter. Cambridge Advisors Inc.’s holdings in Danaher were worth $2,344,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of DHR. Benjamin Edwards Inc. increased its holdings in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares during the last quarter. Wedge Capital Management L L P NC lifted its position in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after buying an additional 38 shares during the last quarter. Certified Advisory Corp boosted its stake in Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after buying an additional 40 shares during the period. Meridian Financial Partners LLC boosted its stake in shares of Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares during the period. Finally, Kovack Advisors Inc. raised its holdings in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.4 %

DHR stock opened at $238.41 on Friday. The stock has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $234.85 and a 200 day moving average of $253.32.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. Sell-side analysts forecast that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analysts Set New Price Targets

DHR has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Citigroup decreased their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Raymond James cut their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird lowered their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.